Agreements

* On July 25, 2013, Eurofins Scientific, a  leader in food, environment and pharmaceutical products testing, has signed an agreement with GE Healthcare for the exclusive right to offer GE Healthcare’s Cytiva™ Cardiomyocytes for drug discovery and early development cardiotoxicity screening services. The agreement allows Eurofins Panlabs to provide a unique offering for an early predictive measure of cardiac toxicity and function in a cost-effective and time-efficient manner compared to current expensive and time-consuming animal testing models. The initial range of cardiotoxicity screening services covered by the exclusive right will be expanded during the term of the agreement. GE Healthcare is pioneering the development of human cell-based models such as Cytiva Cardiomyocytes, which provide a biologically relevant alternative to current cell models and primary cells for predictive cardiotoxicity testing.